**CURRICULUM VITAE**

**Kwame Osei, M.D, FACE,FACP**

**[Business Address]{.underline}**

491 McCampbell Hall

1581 Dodd Drive

Columbus, OH 43210

E-mail:osei-1@medctr.osu.edu

**[Phone]{.underline}**

\(614\) 292-3800 Office

\(614\) 292-1550 Fax

###### Education

1971-76 University of Ghana Medical School, Accra, Ghana

MB. Ch B.

1976-77 University of Ghana Medical School, Accra, Ghana

Rotating Internship

1978-79 Hahnemann Medical College and Hospital

Philadelphia, PA

Residency in Anatomical and Clinical Pathology

82. Episcopal Hospital, Philadelphia, PA

Affiliate of Temple University School of Medicine

Residency in Internal Medicine

**[Academic Positions]{.underline}**

**A.** **The Ohio State University College of Medicine, Columbus, Ohio**

1982-84 Fellow in Endocrinology and Metabolism

1984-89 Assistant Professor of Medicine, Division of Endocrinology and
Metabolism

1989-1995 Associate Professor of Medicine, Division of Endocrinology,
Diabetes and

Metabolism

1995- **Professor of Medicine,** Division of Endocrinology, Metabolism
and Metabolism

**B.** **The Ohio State University College of Education, Columbus,**

> **Ohio**

1995. Associate Professor of Health Education, and Recreation, Division
      of Exercise

Physiology

1995- **Professor of Health Education and Recreation,** Division of
Exercise Physiology

**C. 1996 - Director, Division of Endocrinology, Diabetes and
Metabolism**

**D.** 6/1999

-1/2000 **Interim Chair,** Department of Internal Medicine and Chief
Executive Officer of DMF of Ohio Inc.

**E.** 6/2000- **Associate Director,** General Clinical Research Center

**[Board Certification and Licensure]{.underline}**

**Diplomate, American Board of Internal Medicine**

Board Certified (1982)

**Diplomate, Subspecialty: Endocrinology & Metabolism,**

Board Certified (1985)

Pennsylvania

Ohio

DEA

**[PROFESSIONAL MEMBERSHIPS]{.underline}**

Fellow, American College of Physicians (FACP)

Fellow, American Association of Clinical Endocrinologist(FACE)

American Federation of Clinical Research (AFCR)

American Society of Internal Medicine

Central Society for Clinical Research

Ohio Society of Internal Medicine

Ghana Medical Association

American Diabetes Association (ADA)

Central Ohio Diabetes Association (CODA)

Endocrine Society

National Medical Association

American Association for the Advancement of Science

President\'s Club, The Ohio State University

Fellow, International Society of Hypertension In Blacks

#### RESEARCH INTEREST

1.  Ethnicity and glucose regulation, Insulin action and type 2 diabetes
    with special emphasis on the West African Diaspora.

2.  Pathogenesis of type 2 diabetes and obesity in African Americans

3.  Endocrine Evaluation of Pancreas allograft Transplant recipients

**[HONORS/ AWARDS:]{.underline}**

1\. Clinical Associate Physician Award, NIH (1985‑88)

2\. Upjohn Young Investigators Recognition Award (1986, 1987)

3\. Bremer Foundation Award (1987‑88)

4\. Alpha Omega Alpha (1988)

5\. Veterans Administration Equal Employment & Opportunity (EEO)
Recognition Award for

> Scientific Achievement (1992)
>
> 6\. Federal Employee of the Year Award for Professional/Scientific
> Section (1992)
>
> 7\. President American Diabetes Association, Ohio Affiliate, 1995

8\. Board of Trustees, American Diabetes Association, Ohio Affiliate

9\. Ohio Delegate for National American Diabetes Association

10\. Nominee, George Martin Award for the College of Medicine, 1996

11\. Fellow, American Association of Clinical Endocrinologist

12\. Fellow, International Society of Hypertension in Blacks

13\. Fellow , American College of physicians (FACP) 1996

14. Pfizer Visiting Professorship, Howard University Medical Center,
    Washington, DC, April,

> 1998
>
> 15.Pfizer Visiting Professorship, DC General Hospital, Affiliate of
> Georgetown University Medical Center, Washington, DC, September, 1998

16. Mercy Endowed Visiting Professor, Medical College of Ohio, Toledo,
    April, 2000.

**Journal/Grant Reviewer**

1\. Diabetes Care

2\. Journal of Clinical Endocrinology & Metabolism

3\. American Journal of Medicine

4\. Diabetes

5\. New England Journal of Medicine

6\. Annals of Internal Medicine

7\. Editor: Endocrinology (Medical Information Systems) 1993-1995

8\. Veterans Administrations Merit Award

9\. Journal of American Medical Sciences

> 10\. Metabolism

11\. American Journal of Obstetrics & Gynecology

> 12\. Abstracts for National American Diabetes Association (ADA)
> Scientific Sections

13\. Scientific Section, Endocrine and Metabolic Section, NIH (Ad hoc
Committee)

14\. Institutional:

a\) Roessler Scholarship

b\) University Seed Grant

c\) Landacre Program

d\) Davis Award

15\. Central Ohio Diabetes Association( 1986-1995)

16. Scientific Study Section, Research in Minority Institutions, NIH,
    1995-

> present

17\. Scientific Study Section, Metabolism Subcommittee B, NIH,1996 -
present

18. Chair, Endocrinology Section, National Medical Association of Black

> Physicians 1995-present
>
> 19\. Chair, Endocrinology Section, American Federation of Clinical
> Research 1995-present

20\. Chair, Search Committee, Division of Endocrinology, Diabetes and
Metabolism

21\. Member, Search Committee, Department of Biochemistry

22. Member, Department Representative University Senate

23. Member, Search Committee, Department of Biochemistry

24. Member. Search Committee, Department of Ophthalmology

25. Member, Medical Research and Development Committee

26. Member, University Promotion and Tenure Committee

27. Member, College of Medicine Research Management Committee

**[OSU Student Participation]{.underline}**

1\. Medical Student Advisor

> 2\. Housestaff Resident Advisor

3\. Physical Diagnosis Program

4\. Faculty Supervisor for Roessler Scholarship Program

5\. Medical II and III Programs

6\. Faculty coordinator for Minority Faculty and Student Advisory
Committee

> 7\. Advisor/mentor for the Ohio State University Black Medical
> Students
>
> 8\. Faculty Advisor for Research Students and Postdoctoral Research
> Fellows
>
> A. [Students (6)]{.underline}
>
> B. [Postdoctoral]{.underline} (4)

**Regional, National and International Conferences and Symposium**

1\. Program Director: Symposium, \"Update Workshop in Diabetes:
Pathogenesis and treatment of noninsulin-dependent diabetes mellitus\",
Columbus, OH, April, 1991, 1993.

2\. Chairman: Scientific Section, Annual American Diabetes Association
Meeting, 1991.

3\. Program Director: Symposium, \"Second Annual Diabetes Workshop:
Pathogenesis and Treatment of Noninsulin-dependent diabetes mellitus:
Racial, Age and Gender Perspectives, Columbus, Ohio, April, 1993.

4\. Program Director: International Symposium **\" First World Congress
on Diabetes in Developing Countries, Africa and Tropics\"** Accra,
Ghana, May 15-17, 1995.

5\. Chairman, Endocrinology and Metabolism Subcommittee of Central
Society of Clinical Research(CSCR) 1995- present

6.  Program Director: Endocrinology Section of National Medical
    Association of Black Physicians, Chicago, IL, 1995- present

7.  Program Director, Bi - Annual Diabetes Update: 1985 - present

**[Community Advocacy/ Service]{.underline}**

1\. Ghana Broadcasting Corporation, Accra, Ghana @ World Congress on
Diabetes in Developing Countries, Africa and Tropics @ May,1995

2\. National Press Club, Washington, DC A African American Diabetes
Initiative@ Feb, 1996

3\. Channel 4, Columbus, Ohio, Diabetes Telethon, Columbus, Ohio, Feb,
1996

4\. WCKX 106.3 FM A Diabetes in African Americans@ April 1996

5\. Channel 3 A Ohio State Health Month - Diabetes in Minorities@ April
1996

6\. Voice of America A Diabetes and the World@ June 1996.

7\. Channel 21 A Window on Africa ; Diabetes in the Developing
Countries, Africa and the Tropics, Accra, Ghana, May 15-17,1995

[COMMITTEES]{.underline}

[Local/Regional]{.underline}

> 1\. Member, Human Biomedical Research Review Committee (1986-1995).

2\. Member, Human Organ Transplant Committee, The Ohio State University.

> 3\. Member, Student and Housestaff Educational Committee (AERC),
> Department of Internal Medicine

4\. Member, Med IV Curriculum Subcommittee, Department of General
Internal Medicine.

> 5\. Member, Scholarship Fund Committee, National Medical Association,
> Central Ohio Chapter.
>
> 6\. Participant, Round Table Conference on Diabetes in Black
> Americans, Washington, DC, (9/87).

7\. Member, Academic Enrichment Program Committee, College of Medicine

> a\. Member, Learning Skills Subcommittee, AERC, College of Medicine.
>
> b\. Member, Admission Committee for Post-Baccalaureate Program.

8.  Co-chairman, Endocrinology & Metabolism Section, Midwest American
    Federation of

> Clinical Research (AFCR) Meeting, Chicago, IL, October, 1989.
>
> 9\. Participant, Symposium on Cardiovascular Risk Factors: Focus on
> HDL- Cholesterol, Atlanta, GA, April, 1990.

10. Guest speaker, Annual Meeting of the National Medical Association of
    Black

> Physicians, Columbus Chapter, Columbus, OH, April, 1990.
>
> 11\. Department Liaison, The Ohio State University College of Medicine
> Research Forum.
>
> 12\. Mentor and Advisory Committee, Black Medical Students, The Ohio
> State University.
>
> 13\. Co-chairman, American Diabetes Association, Scientific Section
> for Annual Meeting, Columbus, Ohio, 1991.
>
> 14\. Member, Central Ohio Diabetes Association Research Committee.
>
> 15\. Member, Med II Academic Program Committee

16\. Member, Board of Trustees, American Diabetes Association, Ohio
Affiliate

4.  17 President American Diabetes Association, Ohio Affiliate, 1995
    --96

    18\. Member, College of Medicine Management Committee

    19\. Member, Ophthalmology Search Committee

    20\. Member, Department of Medicine Promotion and Tenure Committee

    21\. Member, University Promotion and Tenure Committee

    22\. Member, College Transplant Committee

    23\. Member and Chair, OSU Diabetes Center Committee

    24\. Member and Chair, OSU Islet Cell Program Committee

[National]{.underline}

> 1\. Mentor, National Medical Association of Black Physicians

2.  Member, The National Organ Procurement and Transplantation Network,
    Scientific

> Advisory Committee, United Network of Organ Sharing (UNOS).

a\) Chairman, Pancreatic Subcommittee, 1992-94

3.  Member, External Advisory Committee, Health Issues in African
    Americans, Urban

> Medical Research Center, Baltimore, MD.

4.  Member, Scientific Advisory Committee, Health Issue Publications in
    African

> Americans, Heart and Soul Magazine, Pittsburgh, PA.

5\. Adhoc Study Section NIH NDDK; Diabetes Prevention Program

6\. Study Section NIH GCRC: Research Centers in Minority Institutions

7\. Study Section NIH NDDK Subcommittee B. Metabolism/Endocrinology

8.  General Clinical Research Center, Site Visit Committee

9.  Member, National Medical Association of black physicians.

10. Member, National Diabetes Education Program Steering Committee

11. Member, Ranch Hand Advisory Committee

12. Member, Pfizer Visiting Professorship Program

13. Member, National Committee on Health Care Disparities

14. Member, Scientific Committee for Programs-ISHB

[Consultation]{.underline}

**Past:**

1\. NIH NDDK Prevention of Diabetes Program (DPP)

> **Pharmaceutical/industry**

1.  Member, Scientific Advisory Committee, NovoNordisk Pharmaceutical
    Inc.

2.  Member, Scientific Advisory Committee, Eli-Lilly/ Takeda
    Pharmaceutical Inc

3.  Member, Scientific Advisory Committee, Aventis

4.  Member, Ranch Handers Commission, US. Department of Human Services

**[GRANTS/CONTRACTS]{.underline}**

A. **Funded**:

> a\) Current Funding

## National

1\. RFA, NIDDK, NIH (7/1/94 - 6/30/2001) Co-PI (7% WOC)

2\. RFA, NIHBL, NIH (1999-2008) PI (OSU Site) (25% )

3\. RFA, NIHBL, NIH (1999-2006) PI (OSU Site) (15%)

4.R0034, GCRC, NIH (1996-2001, Associate Director (30%)

## 

## Regional/State

1.  Commission of Minority Health, State of Ohio - (7/1/2001-6/30/2001)
    PI

2.  The Ohio State Commission of Minority Health - (7/101-6/30/02) PI

# Pharmaceutical

> 1 NovoNordisk (PI)
>
> 2\. PPD/Takeda (PI)
>
> 3\. Pfizer (PI)
>
> 4\. Aventis (PI)

5\. Glaxo Smith Kline (PI)

6\. Eli-Lilly (PI)

**Investigator Initiated**

> Glaxo Smith Kline; Etiological differences in insulin secretion and
> insulin action in Blacks and White Americans with varying degrees of
> glucose tolerance. The role of Tumor Necrosis Factor-alpha. **[--
> PI]{.underline}**
>
> **b) Previous Funding**

12. 1\. Clinical Associate Physician, National Institutes of Health,
    (1985‑88), PI.

2\. NIH RO 13 Conference Grant PI (1995 -96) PI

3\. RO1, NIDDK, NIH (7/1/94 - 6/30/99) PI

4\. National American Diabetes Association (ADA), (1991-94), PI

# Regional/State

> 1\. Central Ohio Diabetes Association
>
> (1985‑86), PI
>
> (1987‑88), PI
>
> (1989-90), PI
>
> (1990-91), PI
>
> (1993-94), PI

2\. AHA, Ohio Affiliate (7/1/94-6/30/97) Co -- Investigator

13. University Bremer Award, (1987‑88), PI

    University Interdisciplinary Seed Grant, (1993-95), Co-PI

**Pharmaceutical**

> 1\. Revlon USV Pharmaceuticals, (1984‑85), Co-PI
>
> 2 Sandoz Pharmaceuticals
>
> (1986‑87), PI
>
> (1988‑89), PI
>
> 3\. Upjohn Pharmaceutical Companies, (1989-90), PI
>
> 4\. Pfizer Pharmaceutical Company,
>
> (1990-91), PI
>
> (1992-93), PI
>
> 6\. The Upjohn Pharmaceutical Company, (1992-93), PI
>
> 7\. Parke Davis Pharmaceutical Research, (1993-95), PI

8\. Parke Davis, Warner Lambert (2/1/95 - 6/30/97) PI

9\. Bristol Myers and Squibb (7/1/95 -6/30/99) PI

10\. NovoNordisk (1999-2001) PI

**B. Approved but not funded**

> 1\. American Diabetes Association, National, (1985-86), PI
>
> 2\. American Diabetes Association, Regional, (1985-86), PI
>
> 3\. First Award (NIH), (1987-89), PI
>
> 4\. Sandoz Pharmaceuticals, (1987‑88), PI
>
> 5\. American Heart Association, (1990-91), PI
>
> 6\. Central Ohio Diabetes Association, (1992-93), PI
>
> 7\. R01 (NIH), \"Glucose, Insulin & Blood Pressure in African
> Descendants\", (1994-99), PI.
>
> 8\. RO1 (NIH) \"Effect of Weight Loss on Outcomes in Severe, Obesity"
> Co-investigator.

**[PUBLICATIONS]{.underline}**

> **86 [ORIGINAL PEER - REVIEWED ARTICLES (80% FIRST
> AUTHORSHIP]{.underline} [PAPERS)]{.underline}**

**[PUBLICATIONS]{.underline}**

[Refereed Articles]{.underline}

1\. Adjepon-Yamoah KK, Owusu SK, [**Osei K**,]{.underline} Archampong
EQ, Zwana SLV. A case of phaeochromocytoma treated surgically. Ghana Med
J 1979 18:276-80.

2\. **[Osei K]{.underline}**, Falko JM, Pacht E, Wall R, Goldberg RF.
Primary adrenal insufficiency manifesting as malignant lymphoma. Arch
Int Med 1983;143:1791‑2.

3\. **[Osei K]{.underline}**, Nelson K, Stephens R, Falko JM. The
mechanism of diabetogenic effect of Pentamidine: [in vivo]{.underline}
and [in vitro]{.underline} studies in malignant insulinoma. Ann Int Med
293, 1159-1162, 1985

4\. **[Osei K]{.underline}**, Falko JM, O\'Dorisio TM, Adam DR, Cataland
S. Decreased serum C‑peptide/insulin molar ratios after oral glucose
ingestion in hyperthyroid patients. Diabetes Care 1984;7:472‑5.

5\. **[Osei K]{.underline}**, Falko JM, O\'Dorisio TM, Adam DR, Cataland
S. Significance of spontaneous ketonuria and C‑peptide in obese type II
diabetic patients. Diabetes Care 1984;7:442‑5.

6\. **[Osei K]{.underline}**, Kramer DS, Malarkey WB, Falko JM.
Pregnancy complicated by insulinoma. Am J Med Sciences 1984;288:133‑6.

7\. **[Osei K]{.underline}**, O\'Dorisio TM, Adam DR, Falko JM.
Concomitant insulin and sulfonylurea therapy in type II diabetic
patients: effects on glucoregulation and lipid metabolism. Am J Med
1984;77:1002‑9.

8\. **[Osei K]{.underline}**, Falko JM. Clinical features and diagnosis
of 16 consecutive insulinoma patients: cost‑ineffectiveness of
non‑invasive imaging modalities. Ohio Med J 1984;80:864‑9.

9\. **[Osei K]{.underline}**, Chiemchanya S, Zatuchni J. Empyema due to
salmonella typhimurium with underlying alveolar cell carcinoma. Southern
Med J 1984;77:234‑6.

10\. **[Osei K]{.underline}**, O\'Dorisio TM, Adam DR, Falko JM. Gastric
inhibitory polypeptide (GIP) responses after oral glucose ingestion in
hyperthyroidism. Diabetes Care 1985;8:436‑9.

11\. **[Osei K]{.underline}**, O\'Dorisio TM, Craig EL, George JM,
Fields PG, Cataland S. Abnormal retinal artery responses to stress in
type I diabetic patients. Am J Med 1985;78:595‑601.

12\. **[Osei K]{.underline}**, Falko JM. Serum C‑peptide levels
determine glycemic responses in type II diabetic patients treated with
combination of insulin and sulfonylurea agent. Am J Med Sci
1985;289:148‑53.

13\. **[Osei K]{.underline}**, O\'Dorisio TM. Malignant insulinoma:
Effects of a somatostatin analogue (Compound 201‑995) on serum glucose,
growth and gastro‑entero‑pancreatic hormones. Ann Int Med
1985;103:223‑5.

14\. **[Osei K]{.underline}**, Falko JM, Adam DR, O\'Dorisio TM.
Decreased C‑peptide/insulin molar ratios in hyperthyroid patients.
Diabetes Care 1985;8:524‑5.

15\. Falko JM, **[Osei K]{.underline}**. Combination of insulin and
glyburide in type II diabetes mellitus: effects on lipoprotein
metabolism and glucoregulation. Am J Med 1985;79:92‑101

16\. **[Osei K]{.underline}**, Falko JM, O\'Dorisio TM, Fields PG,
Bossetti B. Gastric inhibitory polypeptide responses and glucose
turnover rates after natural meals in type II diabetic patients. J Clin
Endocrinol Metab 1986;62:325‑30.

17\. **[Osei K]{.underline}**. Clinical evaluation of determinants of
glycemic control: A new approach using serum glucose, C‑peptide and body
mass indexes in type II diabetic patients. Arch Int Med 1986;146:281‑5.

18\. **[Osei K]{.underline}**, Falko JM. Chronic hyponatremia associated
with diabetic amyotrophy. Arch Int Med 1986;146:534‑6.

19\. **[Osei K]{.underline}**, Falko JM, Fields PG, Bossetti B,
O\'Dorisio TM. The effects of carbohydrate‑enriched meals on glucose
turnover and metabolic clearance rates of glucose in type 2 diabetic
patients. Diabetologia 1986;29:100‑5.

20\. **[Osei K]{.underline}**, Weber PA, Falko JM. Coexistence of
diabetes mellitus, optic atrophy and sensorineural deafness: case report
and review of literature. Annals of Ophthalmology 1986;18:196‑8.

21\. **[Osei K]{.underline}**, Holland G, Falko JM. Indapamide: Effects
on apoprotein, lipoprotein and glucoregulation in ambulatory diabetic
patients. Arch Int Med 1986;146:1973‑77.

22\. **[Osei K]{.underline}**, Holland G. Altered C‑peptide/insulin
molar ratios and glucose turnover rates after stimulation in nondiabetic
offsprings of type II diabetic patients. Metabolism 1987;36:122‑7.

23\. **[Osei K]{.underline}**. Ambulatory and exercise‑induced blood
pressure responses in type I diabetic patients and normal subjects. Diab
Res Clin Prac 1987;3:125‑34.

24\. **[Osei K]{.underline}**, Bossetti B, Holland GC, Falko JM.
Metabolic effects of fructose as a natural sweetener in the physiologic
meals of type II diabetic patients. Am J Med 1987;83:249‑55.

25\. **[Osei K]{.underline}**. The role of splanchnic glucose output in
determining glycemic responses after mixed meal in type II diabetic
patients and normal subjects. Pancreas 1987;2:386‑92.

26\. **[Osei K]{.underline}**, Holland G. Clinical correlates of basal
hepatic glucose output and metabolic clearance rate of glucose using
glucose‑C‑peptide body mass indexes in ambulatory type 2 diabetic
patients. Diabetic Research 1987;5:181‑7.

27\. **[Osei K]{.underline}**. Use of serum C‑peptide in the selection
of therapy for elderly patients with type II diabetes. Geriatrics
1988;7:19-34.

28\. O\'Dorisio, TM, Gaginella TS, O\'Dorisio MS, Meleca RN, Wray DA,
**[Osei K]{.underline}**. Sandostatin; Assay and efficacy in VIPOMA and
insulin. In: O\'Dorisio, TM, ed. Sandostatin in the treatment of GEP
endocrine tumors. New York: Springer-Verlag, 1989:43-52.

29\. **[Osei K]{.underline}**, Mazzaferri EL. Duplication cyst of
esophagus associated with membranous glomerulonephritis in a patients
with type 1 (insulin-dependent) diabetes. Medical Rounds 1989;2:308-19.

30\. **[Osei K]{.underline}**. Dietary fructose as a natural sweetener
in poorly-controlled type 2 diabetics: chronic effects on glucose,
lipoprotein and apolipoprotein metabolism. Diabetic Medicine
1989;6:506-11.

31\. **[Osei K]{.underline}**, O\'Dorisio TM, Malarkey WB, Craig EL,
Cataland S. Metabolic effects of long-acting somatostatin analogue
(Sandostatin) in type 1 diabetic patients on conventional therapy.
Diabetes 1989;38:704-9.

32\. **[Osei K]{.underline}**. Defective insulin-mediated splanchnic
glucose regulation and glucose clearance: Early glucose homeostatic
defects in nondiabetic, young offspring of NIDDM patients. Diabetes
Research 1989;12:7-13.

33\. **[Osei K]{.underline}**. Differential effects of carbohydrate‑ and
protein‑enriched mixed meal on endogenous insulin secretion, hepatic
insulin extraction and insulin clearance in nondiabetic offspring of
type II diabetic patients and normal controls. Diabetes, Nutrition and
Metabolism 1990;2:299-307.

34\. **[Osei K]{.underline}**. Increased basal glucose production and
utilization in nondiabetic, first-degree relatives of patients with
noninsulin-dependent diabetes mellitus (NIDDM) patients. Diabetes
1990;39:597-601.

35\. **[Osei K]{.underline}**, Henry ML, O\'Dorisio TM, Sommer BG,
Ferguson RM. Physiological and pharmacological stimulating hormone
secretion in type I diabetic allograft pancreas recipients. Diabetes
1990;39:1235-42.

36\. **[Osei K]{.underline}**. Predicting type 2 diabetes in persons at
risk. \[Editorial\]. Ann Int Med 1990;113:905-7.

37\. Henry ML, **[Osei K]{.underline}**, O\'Dorisio TM, Sommer BG,
Ferguson RM. Concomitant reduction in urinary amylase and acute
first-phase insulin release predict pancreatic allograft transplant
rejection in type I diabetic patients. Clinical Transplantation
1991;5:112-120.

38\. Bello F, Falko JM, O\'Dorisio TM, **[Osei K]{.underline}**. The use
of continuous subcutaneous octreotide infusion in brittle type 1
diabetic patients. Diabetic Med 1991 8:385-7.

39\. **[Osei K]{.underline}**, Cottrell DA, Bossetti B. Relationships of
obesity indices to serum insulin and lipoproteins in relatives of black
patients with noninsulin-dependent diabetes mellitus. Int J Obesity
1991;15:441-51.

40\. **[Osei K]{.underline}**, O\'Dorisio TM, Malarkey WB, Cataland S.
Continuous subcutaneous octreotide infusion (CSOI): Relationships
between metabolic effects and octreotide clearance in insulin-dependent
(type 1) diabetes. J Lab Clin Med 1991;118:56-64.

41\. **[Osei K]{.underline}**, Cottrell DA, Orabella MM. Insulin
sensitivity, glucose effectiveness and body fat distribution patterns in
nondiabetic offspring of patients with noninsulin-dependent diabetes
mellitus (NIDDM). Diabetes Care 1991;14:890-896.

42\. Cottrell DA, O\'Dorisio TM, Tesi R, Ferguson R, Sommer B, Henry M,
**[Osei K]{.underline}**. Hypoglycemia following successful pancreas
transplantation. Diabetes Care; 1991:14:1111-13.

43\. **[Osei K]{.underline}**, Henry MC, O\'Dorisio TM, Tesi RJ, Sommer
BG, Ferguson RM. Pancreatic islet cell secretion following pancreas
allograft transplantation in type 1 diabetic recipients. The Ohio State
University College of Medicine Research Forum 1991;5:61-6.

44\. **[Osei K]{.underline}**, Cottrell DA, Henry ML, Tesi RJ, Ferguson
RM, O\'Dorisio TM, . Insulin insensitivity and glucose effectiveness in
type 1 diabetic allograft pancreas recipients. Transplantation
Proceedings 1992;24:828-30.

45\. **[Osei K]{.underline}**, Cottrell D, Harris B. Differences in
basal and stimulated glucose homeostasis in nondiabetic, first-degree
relatives of black and white patients with type 2 diabetes mellitus. J
Clin Endo Metab 1992;75:82-6.

46\. Cottrell DA, Henry ML, O\'Dorisio TM, Tesi RJ, Ferguson RM, **[Osei
K]{.underline}**. Sequential metabolic studies of pancreas allograft
function in type 1 diabetic recipients. Diabetic Medicine 1992;9:438-43.

47\. Barone GW, Henry ML, Elkhamas EA, **[Osei K]{.underline}**, Tesi
RJ, Ferguson RM. Pancreatic exocrine \"burnout\" following
transplantation. Transplantation Proceedings 1992; 24:831-2.

48\. **[Osei K]{.underline}**, Cottrell DA, Henry ML, Tesi RJ, Ferguson
RM, O\'Dorisio TM. Minimal model analysis of insulin sensitivity and
glucose effectiveness in type 1 diabetic allograft pancreas recipients.
Diabetologia 1992;35:676-80.

49\. **[Osei K]{.underline}**. The effects of superphysiologic
hyperinsulinemia on nonoxidative glucose disposal and lipid metabolism
in glucose-tolerant offspring of patients with noninsulin-dependent
diabetes mellitus (NIDDM). Diab Res & Clin Pract 1992; 17: 169-82.

50\. Ezenwaka CE, Akanji AU, **[Osei K]{.underline}**, Adejuwon CA,
O\'Dorisio TM, Cottrell, DA, Akinlade KS. Glucose and insulin responses
to intravenous glucose challenge in relatives of Nigerian patients with
NIDDM. Diab Res Clin Pract 1993;20:173-4.

51\. **[Osei K]{.underline}**, Cottrell DA, Adejuwon CA, Ezenewaka EC,
Akanji AO, O\'Dorisio TM. Serum insulin and glucose concentrations in
persons at high risk for type 2 diabetes: A comparative study of
African-Americans and Nigerians. Diab Care 1993;16:1367-75.

52\. Schuster D, O\'Dorisio TM, **[Osei K.]{.underline}** Defective beta
and alpha cell responses to stimulation in patients with acanthosis
nigricans. Am J Med Sci 1994;307:342-5.

53\. **[Osei K,]{.underline}** Henry M, Tesi R, Fergurson R.
Differential effects of systemic insulin delivery and prednisone on
tissue glucose resistance and insulin sensitivity in insulin-dependent
diabetes mellitus pancreas recipients. Trans­plan­tation Pro­ceedings,
1994; 26:480-82.

54\. **[Osei K]{.underline}**. Genetic basis of the aetiology of
noninsulin-dependent diabetes (NIDDM). In: Robbins DC, Leslie DL, eds.
Diabetes: Clinical Science in Practice. London: Cambridge Univerity
Press. 170-188,1995

55\. Landon M, **[Osei K,]{.underline}** Platt M, O\'Dorisio T, Samuels
P, Gabee S. Differential effects of body fat distr­ibu­tion on glucose and
insulin metabolism during pregnancy. Am J. Obs. Gyne 171, 875 -883,
1994.

56\. **[Osei K]{.underline}**. Cottrell DA. Minimal model analyses of
insulin-sensitivity and glucose-dependent glucose disposal in black and
white Americans. E. J Clin Invest, 24, 843- 850,1994.

57\. Gao J, Sherman WM, McCune SA, **[Osei K]{.underline}**. Effects of
acute exercise on whole body insulin action in obese male SHHF/NMCC-CP
rats. J Appl Physio,77,534-541,1994

58\. **[Osei K,]{.underline}** Schuster D. Ethnic differences in
secretion, sensitivity and hepatic extraction of insulin in black and
white Americans. Diab Med 11,755- 762,1994

59\. **[Osei K]{.underline}**, Schuster D. Metabolic characteristics of
African Descendants: A comparative study of African Americans and first
generation African migrants. Diabetologia 38, 1103 - 1109, 1995

60\. [**Osei K,**]{.underline} Schuster D. Ethnic differences in
secretion, sensitivity and hepatic extraction of

insulin in black and white Americans. Diab Med 11,755- 762,1994

61\. [**Osei K**,]{.underline} Schuster D, Effects of heparin -induced
non esterified free fatty acid on minimal

> model - derived insulin sensitivity in individuals with varying
> degrees of glucose intolerance. Diab Med 12, 911 - 915, 1995

62\. [**Osei K**.]{.underline} Schuster D. Decreased insulin sensitivity
but not noninsulin -dependent glucose

disposal in African(Ghanaian) immigrants. Am J Clinical Sci 311,113-121,
1996

63\. **[Osei K]{.underline}.** Schuster DA, Effects of ethnicity and
race on insulin sensitivity, ambulatory blood

pressure and heart rates in three ethnic populations: Comparative
studies in African

Americans, Ghanaian immigrants and white Americans. Am. J. Hypertension
9:

1157 - 1164,1996

64\. **[Osei K]{.underline}.** Schuster DA, Race and Ethnicity determine
serum insulin and c-peptide

> concentrations in insulin secretion and hepatic insulin extraction and
> insulin clearance:
>
> Comparative studies of three populations of West African Ancestry
> Americans, and white
>
> Americans; Metabolism 46, 53-58,1997.

65. **[Osei K]{.underline}**, Gaillard T, Schuster DP, Pathogenetic
    mechanism of impaired glucose tolerance

> and type 2 diabetes in African Americans: The significance of insulin
> secretion, insulin
>
> sensitivity and glucose effectiveness. Diabetes Care, 20, 396-404,1997

66. Gaillard, T, **[Osei K]{.underline}**, Schuster D, Green Patricia,
    Bossetti B, The impact of socioeconomic

> status on the risk factors for type 2 diabetes and cardiovascular
> diseases in high risk African
>
> Americans: Implications for Syndrome X. Diabetes Care 20, 745-
> 752,1997

67. **[Osei K,]{.underline}** Gaillard T, Schuster D. History of
    gestational diabetes leads to distinct metabolic

> alterations nondiabetic African Americans with parental history of
> type 2 diabetes. Diabetes Care 21, 1250-1256,1998

68. Schuster D, Kien CL, **[Osei K]{.underline}.** Differential effects
    of obesity on insulin sensitivity and insulin secretion in African
    American and Caucasian adolescents 316, 361-367,1998 Amer J.Clinic
    cience 316, 361-367,1998

69. [**Osei K**,]{.underline} Schuster DA. Race and Ethnicity determine
    serum insulin and c-peptide

> concentrations in insulin secretion and hepatic insulin extraction and
> insulin clearance: Comparative studies of three populations of West
> African Ancestry Americans, and white Americans; Metabolism 46,
> 53-58,1997.

70. Gaillard, T. [**Osei K**,]{.underline} Schuster D. Green Patricia,
    Bossetti B, Socioeconomic and

> demographics do not predict risk for diabetes in African Americans.
> The Diab Educators[.]{.underline} 23,294-300,1997.

71. Gaillard, T, **[Osei K]{.underline}**, Schuster D. Green Patricia,
    Bossetti B, The impact of socioeconomic status on the risk factors
    for type 2 diabetes and cardiovascular diseases in high risk

> African Americans: Implications for Syndrome X. Diabetes Care 20, 745-
> 752,1997.

72. **[Osei K]{.underline}**. Schuster DA, Effects of ethnicity and race
    on insulin sensitivity, ambulatory blood

> pressure and heart rates in three ethnic populations: Comparative
> studies in African
>
> Americans, Ghanaian immigrants and white Americans. Am. J.
> Hypertension 9: 1157 --
>
> 1164,1996

73. Gaillard, T, [**Osei K**,]{.underline} Schuster D, Green Patricia,
    Bossetti B, The impact of socioeconomic

> status on the risk factors for type 2 diabetes and cardiovascular
> diseases in high risk African
>
> Americans: Implications for Syndrome X. Diabetes Care 20, 745-
> 752,1997

74. **[Osei K,]{.underline}** Gaillard T, Schuster D. History of
    gestational diabetes leads to distinct metabolic

> alterations nondiabetic African Americans with parental history of
> type 2 diabetes. Diabetes Care 21, 1250-1256,1998

75. Schuster D, Kien CL, **[Osei K]{.underline}.** Differential effects
    of obesity on insulin sensitivity and insulin

> secretion in African American and Caucasian adolescents 316,
> 361-367,1998 Amer J. Clinic Science 316, 361-367,1998

76. Gaillard, T, [**Osei K**,]{.underline} Schuster D, Green Patricia,
    Bossetti B, Gender differences in insulin

> sensitivity and glucose dependent glucose disposal in obese African
> Americans at high risk for type 2 diabetes:. Ethnicity and Disease.
> 8,319-330,1999

77. **[Osei K:]{.underline}** Metabolic Consequences of West African
    Diaspora: Lessons from the thrifty gene. J Lab Clin
    Med.133,98-112,1999

78. **[Osei K]{.underline}.** Post-transplantation hypoglycemia in type
    1 diabetic pancreas allograft recipients.

79. Acta Diabetologica 35, 176-182,1999 Osei K, Insulin resistance and
    systemic hypertension. Am J. Cardiology 84, 331- 361,1999

80. [**Osei K**,]{.underline} Gaillard T, Schuster D, Significance of
    parental history of type 2 diabetes on insulin

> sensitivity and glucose effectiveness in obese nondiabetic offspring
> of African American
>
> parents with type 2 diabetes. Diabetes Care: 22,1594
> -1595,1999.**[Osei K]{.underline}**, Gaillard T.
>
> Schuster D. Cardiovascular risk factors in African Americans with
>
> varying degrees of glucose intolerance: Comparison of New American
> Diabetes Association vs.Old World Health Organization Diagnostic
> Criteria Diabetes Care: 22,1588-1589,1999

83. Amoah AGB, Owusu SK, Saunders JT,Fang WI. Barret E. Woode MKA.
    **[Osei K]{.underline}.**

> Facilities and resources for diabetes care at regional health
> facilities in southern Ghana, Diab Res Clin Pract. 42 123-130,1998

84. Kallaras K, Sparks EA, Schuster DP, [Osei K,]{.underline} Wolley CF,
    Boudoulas H. Integration of Circulatory Mechanisms: Left ventricular
    mass, aortic function and left ventricular

> performance J, Noninvasive Cardiology 3,177-184,1999

85. **[Osei K]{.underline}**. Therapeutics in relation to
    pathophysiology of type 2 diabetes and UKPDS

> Monograph 2000
>
> 86\. Fernando C, Pesavento TE, [Osei K,]{.underline} Henry ML.
> Ferguson RM. Post transplantation diabetes mellitus: increasing
> incidence in renal allograft recipients transplanted in recent years.
> Kidney International. Kidney International, 59,732-737, 2001
>
> 87\. Amoah A.G., [Osei K]{.underline}, Schuster D, Owusu SK, Minimal
> Model Analyses of beta cell function, insulin secretion and glucose
> effectiveness in first degree relatives of Ghanaian patients with type
> 2 diabetes and healthy controls subjects. Ethnicity and
> Disease.11,201-210,2001

88. [Osei K.]{.underline} Effect of Ramipril vs. Amlodipine on renal
    outcomes in hypertensive

> nephrosclerosis. A randomised Controlled Trial. AASK Study Group. JAMA
> 285, 2719 - 2728,2001.

89. **[Osei K]{.underline}**. Is HbA1c a surrogate for Metabolic
    Syndrome in non-diabetic, first degree

> relatives of African American patients with type 2 diabetes?

**[Book Chapter;]{.underline}**

1\. **[Osei K]{.underline}**, Falko JM. Lipid Studies in Cardiology. In:
Warren JV, Lewis RP, eds. Diagnostic Procedures in Cardiology: A
Clinician\'s Guide. Chicago: Year Book Publishers, 1985:196‑210.

2\. **[Osei K]{.underline}**, Falko JM. Atherogenesis in Hypertensive
Diabetics. (Monogram). 1985.

3\. **[Osei K]{.underline}**. Diabetes and hypertension. In: Bowen J,
Mazzaferri EL, eds. Contem­porary Internal Medicine. New York: Plenum
Medical Co, 1989;Vol 2:46-56.

4\. Caruso D, [**Osei K**.]{.underline} Diabetes and hypertension. In:
Bowen J, Mazzaferri EL, eds. Contemporary Internal Medicine. New York:
Plenum Medical Company, 1991;vol 3;107-17.

5\. **[Osei K]{.underline}**. Pathophysiology of type 2 diabetes. In:
Mazzaferri EM, Bar R, eds. Advances in Endocrinology and Metabolism .
Chicago: Mosby, 1992:Vol III;55-87.

6\. **[Osei K,]{.underline}** The impact of ethnicity and race on
hyperinsulinemia, elastic properties of the aorta and cardiovascular
diseases inhuman subjects: A new hypothesis. In Functional Abnormalities
of the Aorta. Harisios Boudoulas, Ed, Futura Publications Company, 1996,
pg 93-101

7\. [**Osei K**,]{.underline} Schuster D, Amoah ABG, Owusu SK.
Pathogenesis of type 1 and type 2 diabetes in Africa: Implications for
transitional Countries. In J of Cardiovascular Risk. Ed. Levitt N.

**[Abstracts:]{.underline}**

1\. **[Osei K]{.underline}**, Nelson K, O\'Dorisio TM, Stephens R, Falko
JM. Effects of Pentamidine on insulin secretion in malignant insulinoma.
Clin Res 1983;31:393A.

2\. **[Osei K]{.underline}**, Nelson K, O\'Dorisio TM, Stephens R, Falko
JM: The mechanism of human diabetogenic effects of Pentamidine.
Endocrine Society 1983;65:1290.

3\. **[Osei K]{.underline}**, O\'Dorisio TM, Cataland S, Adam DR, Falko
JM: Gastric inhibitory polypeptide (GIP) responses after oral glucose
ingestion in hyperthyroidism. Clin Res 1983;31:722A.

4\. **[Osei K]{.underline}**, Falko JM, O\'Dorisio TM, Adam DR, Cataland
S. Ketonuria in obese type II diabetics (OD) determine insulin
dependence. Clin Res 1983;31:725A.

\*\*5. **[Osei K]{.underline}**, Nelson K, O\'Dorisio TM, Stephens R,
Falko JM. The mechanism of diabetogenic effects of Pentamidine.
(Presented at American College of Physicians (ACP) local meeting at
Akron, Ohio, Oct. 14, 1983.)

6\. **[Osei K]{.underline}**, O\'Dorisio TM, Cataland S, Adam DR, Falko
JM. Impaired hepatic extraction of insulin contributes to
hyperinsulinism in hyperthyroidism. Clin Res 1983;31:719A.

7\. **[Osei K]{.underline}**, O\'Dorisio TM, Falko JM. Concomitant
insulin and glyburide therapy in type II diabetic patients: effects on
glucoregulation and lipoprotein metabolism. Clin Res 1984;32:405A.

\*8. **[Osei K]{.underline}**, O\'Dorisio TM, Bossetti B, Fields PG,
Falko JM. Determination of glucose turnover rates with D3‑H‑3 glucose
after a starch (ST), sucrose (SU) and fructose (F) test meals in type II
diabetic patients. (Presented at The National Meeting of American
Federation for Clinical Research, Washington D.C., May 5, 1984, and
Midwest Medical Forum, Madison, Wisconsin, March 1, 1984.) Clinical
Research 252A, 1984.

\*\*9. **[Osei K]{.underline}**, Fields PG, O\'Dorisio TM, Craig EL,
George JM, Cataland S. Abnormal retinal artery response to stress in
type I diabetic patients. (Presented at the Midwest Medical Forum,
Madison, Wisconsin, March 1, 1984, and Landacre Society meeting,
Columbus, Ohio, 1984.) Diabetes 33:747, 1984.

10\. **[Osei K]{.underline}**, O\'Dorisio TM, Fields PG, Bossetti B,
Falko JM. Pancreatic polypeptide (PP) and gastric inhibitory polypeptide
(GIP) responses after starch (ST), sucrose (SU) and fructose (F) meals
in type II diabetic patients. Diabetes 1984;33:596.

11\. **[Osei K]{.underline}**, O\'Dorisio TM, Falko JM. Combination
insulin and sulfonylurea therapy in type II diabetic patients: effects
on glucoregulation and lipoprotein metabolism. Am C Physician Regional
Meeting, Cincinnati, OH, 1984.

\*12. **[Osei K]{.underline}**, Falko JM, O\'Dorisio TM, Bossetti B.
Gastric inhibitory polypeptide (GIP) rather than pancreatic polypeptide
(PP) plays a role in glucoregulation in type II diabetic patients.
(Presented at American Federation for Clinical Research Regional
Meeting, Chicago, Nov., 1984.) Clin Res 1984;32:774A.

\*\*13. **[Osei K]{.underline}**, Falko JM. Serum C‑peptide levels
predict responsiveness to combined insulin‑sulfonylurea therapy in type
II diabetic patients. (Presented at American Federation for Clinical
Research Regional Meeting, Chicago, IL, Nov., 1984.) Clin Res
1984;32:764A.

\*14. **[Osei K]{.underline}**, O\'Dorisio TM, Falko JM, Holland GC,
Bossetti B. Antihypertensive (ATH) Drug Treatment Improves Both Serum
Lipoproteins (LP) and Proteinuria in type I diabetic patients (DM).
(Presented at the American Diabetes Association National Meeting,
Baltimore, MD, June, 1985.) Diabetes 1985;34:368.

\*15. **[Osei K]{.underline}**, Falko JM, O\'Dorisio TM, Bossetti B,
Fields PG. Gastric inhibitory polypeptide (GIP) play a compensatory role
in glucose homeostasis in type II diabetic patients. (Presented at The
Endocrine Society Meeting, Baltimore, MD, June, 1985.) Endocrinology
1985;67:108.

16\. **[Osei K]{.underline}**. Cimetidine (an H~2~‑receptor blocker) has
no acute effects on hypothalamo‑pituitary‑adrenal axis in healthy
subjects. Endocrinology 1985;67:1239.

\*17. Cataland S, O\'Dorisio TM, Bossetti B, **[Osei K]{.underline}**.
Amelioration of Diabetic proteinuria with Acetazolamide. (Presented at
The American Diabetes Association National Meeting, Baltimore, MD, June,
1985.) Diabetes 1985;34:365.

18\. **[Osei K]{.underline}**, O\'Dorisio TM. Effects of somatostatin
(SMS) analogue (Compound 201‑995) on serum glucose, growth and
gastroenteopancreatic hormones in a malignant insulinoma patient. Clin
Res 33:312, 1985.

\*19. **[Osei K]{.underline}**, Bossetti B, Holland GC, Falko JM.
Fructose Supplementation (suppl) of natural meals improves
glucoregulation and apoprotein (apo) metabolism in type II diabetic
patients. (Presented at The American Federation foe Clinical Research
National Meeting, Washington DC, 1985.) Clin Res 1985;33:276A.

\*\*20. **[Osei K]{.underline}**, O\'Dorisio TM. Longterm effects of
Somatostatin analogue (SMS 201‑995) on serum glucose, growth and
gastroenteropancreatic hormones in a malignant insulinoma patient.
(Presented at the Regional meeting of American College of Physicians,
Columbus, OH, 1985.)

\*\*21. **[Osei K]{.underline}**, Bossetti, B, Holland GC, Falko JM.
Fructose supplementation of natural meals improves glucoregulation and
apoprotein metabolism in type II diabetic patients. (Presented at the
Regional meeting of American College of Physicians, Columbus, OH, 1985.)

\*\*22 **[Osei K]{.underline}**. Exaggerated ambulatory and
exercise‑induced BP responses in type I (IDDM) patients. (Presented at
the American Federation for Clinical Research Regional Meeting, Chicago,
IL, 1985). Clin Res 33:533A,1985.

23\. **[Osei K]{.underline}**, Falko JM. Indapamide (IND): Beneficial
effects on BP, apoprotein and lipoprotein metabolism, but not on
glucoregulation in poorly controlled, hypertensive type II diabetic
patients. Clin Res 1985;33:851A.

24\. **[Osei K]{.underline}**. Clinical validation of determinants of
glycemic control using serum glucose, C‑peptide and body mass indices in
type II diabetic (DM) patients. Clin Res 1985;33:827A.

25\. O\'Dorisio TM, **[Osei K]{.underline}**. Paradoxical effects of
Somatostatin (SMS) analog (201‑995) on gastrin releasing peptide (GRP)
and pancreatic polypeptide (PP) during provocative testings in benign
insulinoma. Clin Res 1985;33:877A.

26\. **[Osei K]{.underline}**, O\'Dorisio TM. Chronic effects of
Somatostatin (SMS) analog (201‑995) on glucoregulation may be
independent of suppression of endogenous insulin secretion. Clin Res
1985;33:827A.

\*27. **[Osei K]{.underline}**, Falko JM, Jackson R, McDonald T,
O\'Dorisio TM. Somatostatin analog 201‑995: Uncoupling of effects of
gastrin‑releasing peptide (GRP) on gastrin (G) release. (Presented at
the Symposium of Gastrointestinal Hormones, Vancouver, Canada, 1986.)

\*28. **[Osei K]{.underline}**, Jackson R, O\'Dorisio TM. Somatostatin
(SMS) analog: Long‑term effects on endogenous insulin secretion in a
malignant insulinoma patient. (presented at the Symposium of
Gastrointestinal Hormones, Vancouver, Canada, 1986.)

\*29. **[Osei K]{.underline}**. Postprandial splanchnic glucose
appearance (RA) and early phase insulin release rather than glucose
disposal determine normal glucose tolerance. (Presented at the
International American Diabetes Association Meeting, Anaheim, CA, 1986.)
Diabetes, 1986;35(suppl 1):366.

30\. **[Osei K]{.underline}**, Holland, G. Significance of clinical
correlates of basal glucose fluxes in the selection of drug therapy in
ambulatory type II diabetic patients (DM). Diabetes 1986;35(suppl
1):465.

31\. **[Osei K]{.underline}**, Holland G. Altered C‑peptide/insulin
molar ratios and glucose fluxes in offsprings of type II diabetic
patients. Clinical Research 1986;34:431.

32\. **[Osei K]{.underline}**. Clinical characterization of responders
to oral sulfonylurea agents in type II diabetic patients. Clin Res
1986;34:431.

33\. **[Osei K]{.underline}**, Holland G. Comparison between basal and
post‑stimulation fractional hepatic extraction and C‑peptide/insulin
molar ratios in normal man. Clin Res, 1986.

\*\*34. **[Osei K]{.underline}**, Bossetti B, Holland, G, Falko JM.
Effects of supplemental fructose as a natural sweetener on glycemic
control and apolipoproteins in type II diabetic patients. Clin Res,
1986, (Presented at the American Federation for Clinical Research
Regional Meeting, Chicago, 1986.)

35\. **[Osei K]{.underline}**, Holland G. Bedtime insulin plus daytime
oral sulfonylurea: effects on basal and postprandial glucose fluxes in
type II diabetics. Clin Res, 1986.

36\. **[Osei K]{.underline}**, Significance of post stimulation
fractional hepatic insulin extraction and C‑peptide/insulin molar ratios
in man. Clin Res 1987;35:400A.

37\. **[Osei K]{.underline}**. Exogenous glucose oscillations: effects
of glucose turnover and pancreatic beta cell responses. Clin Res
1987;35:513A

\*38. **[Osei K]{.underline}**, Bossetti, B. Fructose: effects on
glycemic control and lipoprotein metabolism in noninsulin‑dependent
diabetics (NIDDM). Diabetes 1987;36(suppl 1):137 (Presented at the
American Diabetes Association International Meeting, Indianapolis, IN,
1987.)

\*39. **[Osei K]{.underline}**, Effects of insulin distribution on
glucoregulation during combined sulfonylurea and insulin therapy (SIT)
in type II diabetic (DM) patients. (Presented at the American Diabetes
Association International Meeting, Indianapolis, IN, 1987.) Diabetes
1987;36(suppl 1):227

\*40. **[Osei K]{.underline}**, Bossetti B. Fructose supplementation of
natural meals: effects on hepatic glucose output and postprandial
glucose fluxes in type II diabetic patients. (Presented at the Endocrine
Society Annual Meeting, Indianapolis, IN, 1987.) Endocrine Society,
1987.

41\. **[Osei K]{.underline}**. Insulin dissipation rather than somogyi
and dawn phenomena determines fasting hyperglycemia (FHG) in type I
diabetic patients (DM) on conventional therapy. Clin Res 1987;35:845A.

\*\*42. **[Osei K]{.underline}**, O\'Dorisio TM, Sommer BG, Ferguson RM,
Henry ML. Defective acute (first) phase insulin release following
intravenous insulin secretagogues predicts pancreatic transplant failure
in type I diabetic patients. (Presented at the American Federation for
Clinical Research Regional Meeting, Chicago, 1987). Clin Res
1987;35:845A.

\*\*43. **[Osei K]{.underline}**, Altered hepatosplanchnic glucose
appearance (HSGA) and substrate utilization in nondiabetic family
members (NFM) of type II diabetic patients. (Presented at the American
Federation for Clinical Research Regional Meeting, Chicago, IL, 1987).
Clin Res 1987;35:845A.

\*44. **[Osei K]{.underline}**, O\'Dorisio TM, Malarkey WB, Cataland S.
Altered insulin action on hepatic glucose production and glucose
clearance determines early morning hyperglycemia in type I diabetic (DM)
patients. (Presented at the American Federation for Clinical Research
National Meeting, Washington DC, 1988). Clin Res 1988;36:388A.

\*45. **[Osei K]{.underline}**. Early metabolic derangement in
nondiabetic family members of type II diabetic patients. (Presented at
the American Federation for Clinical Research National Meeting,
Washington, DC, 1988, and to be XIII International Congress of Diabetes
in Sydney, Australia, 1988. Diab Res Clin Prac 1988:5(suppl 1):002-096.

\*\*46. **[Osei K]{.underline}**. Resting and postprandial
thermogenesis: relationships with body compositional variables in
relative of type II diabetics. (Presented at the Regional Meeting of
American Federation for Clinical Research Regional Meeting, Chicago,
1988. Clin Res 1988;36:835A.

47\. **[Osei K]{.underline}**. Differential effect of
macronutrient‑enriched meals on hepatic insulin extraction and insulin
clearance of offspring of type II diabetics and healthy subjects. Clin
Res 1988;38:835A.

\*48. **[Osei K]{.underline}** Impaired glucose/insulin-induced
suppressibility of hepatic glucose production: An early defect in
nondiabetic offspring of NIDDM patients. (Presented at the American
Federation for Clinical Research, Washington, DC, 1989.) Clin Res
1989;37:458A.

49\. **[Osei K]{.underline}**. Early alteration in resting energy
expenditure and glucose/insulin-induced thermic effects in offspring of
NIDDM patients. Diabetes 1989;38(suppl 2):438.

50\. **[Osei K]{.underline}**. Defective resting and postprandial energy
expenditure in nondiabetic young first degree relatives of NIDDM
patients. (Presented at the American Federation for Clinical Research
National Meeting, Washington, DC, 1989.) Clin Res 1989;37:457A.

\*51. **[Osei K]{.underline}**. Abnormal insulin-mediated splanchnic
glucose regulation and glucose clearance: An early defect in healthy
offspring of NIDDM patients. (Presented at the American Diabetes
Association National Meeting, Detroit, MI, 1989.) Diabetes 1989;38(suppl
2):306.

\*\*52. **[Osei K]{.underline}**. The primary role of basal hepatic
glucose dysregulation in the genesis of NIDDM: A study of
glucose-tolerant relatives. (Presented at the American Federation for
Clinical Research Regional Meeting, Chicago, 1989.) Clin Res
1989;37:896A.

\*\*53. **[Osei K]{.underline}**, O\'Dorisio TM, Ferguson RM, Sommer BL,
Tesi RJ, Henry ML. Concomitant reduction in urinary amylase and acute
first-phase insulin release predict pancreatic allograft transplant
rejection in type I diabetic recipients. (American Federation of
Clinical Research Regional Meeting, Chicago, 1989.) Clin Res
1989;37:896A.

54\. **[Osei K]{.underline}**, O\'Dorisio TM, Ferguson RM, Sommer BL,
Tesi RF, Henry ML. Physiologic and pharmacologic stimulation of
pancreatic islet hormone secretion in type I diabetic allograft pancreas
recipients. Clin Res 1989;37:897A.

\*55. Cottrell D, Henry M, O\'Dorisio TM, Tesi R, Ferguson R, Sommer B,
**[Osei K]{.underline}**. Clinical and biochemical markers of patients
at risk for profound hypoglycemia after pancreatic transplantation.
(Presented at the American Federation for Clinical Research National
Meeting, Washington, DC, 1990.) Clin Res 1990;38:308A.

56\. **[Osei K]{.underline}**, Cottrell D. Differences in basal
metabolic and energy characteristics of glucose-tolerant relatives of
NIDDM patients and healthy controls. Clin Res 1990;38:569A.

57\. Cottrell D, **[Osei K]{.underline}**,. Hepatic and peripheral
insulin insensitivity in nondiabetic relatives of black patients with
NIDDM. Diabetes 1990;39(suppl 1):1095.

58\. **[Osei K]{.underline}**,. Metabolic effects of altered body fat
distribution in obese and nonobese glucose-tolerant relatives of black
NIDDM patients. Diabetes 1990:39(suppl 1):1095.

\*59. **[Osei K]{.underline}**, O\'Dorisio TM, Malarkey MB, Cataland S.
Dose response metabolic effects of s.c. continuous infusion (CI) of a
potent somatostatin (SMS) analogue. (Endocrine Society National Meeting,
GA.) Endocrinology 1990;572:167.

\*60. **[Osei K]{.underline}**, Cottrell D, Orabella M. Decreased
insulin sensitivity but not glucose effectiveness in offspring of NIDDM
patients. (Presented at the International Diabetes Federation Congress,
Washington, DC, 1991). Diabetes 1991;40:1857.

\*61. **[Osei K]{.underline}**, Cottrell D, Harris B. Early metabolic
differences in black and white relatives of NIDDM patients. (Presented
at the International Diabetes Federation Congress, Washington, DC,
1991). Diabetes 1991;40:126.

\*62. Cottrell D, **[Osei, K]{.underline}**, Henry M, O\'Dorisio T, Tesi
R, Ferguson R. Sequential studies of pancreas allograft function in IDDM
recipients. (Presented at the International Diabetes Congress,
Washington, DC, 1991). Diabetes 1991;40:243.

\*63. **[Osei K]{.underline}**, Cottrell DA, Henry ML, Ferguson RM, Tesi
RJ, O\'Dorisio TM. Insulin insensitivity and glucose effectiveness in
type 1 diabetic allograft pancreas recipients. (Presented at the
American Federation of Clinical Research (AFCR) National Meeting,
Seattle, WA, 1991). Clin Res 1991;39:246A.

\*64. **[Osei K,]{.underline}** Cohen RM, Wary DA, Cottrell DA,
O\'Dorisio TM. Proinsulin component of circulating immunoreactive
insulin fpr glucose-tolerant offspring of patients with NIDDM.
(Presented at the American Federation of Clinical Research (AFCR)
National Meeting, Seattle, WA, 1991). Clin Res 1991;39:246A.

65\. Cottrell DA, **[Osei K]{.underline}**. Alternate day sulfonylurea
therapy (ADS): Metabolic effects in NIDDM patients with secondary
sulfonylurea (SSU) failure. Clin Res 1991;39:446A.

\*66. **[Osei K]{.underline}**, Cottrell DA, Henry ML, Tesi RJ, Ferguson
RM, O\'Dorisio TM. Insulin insensitivity and glucose effectiveness in
type 1 diabetic allograft pancreas recipients. (Presented at the III
International Congress on pancreatic and islet transplantation and
symposium on artificial insulin delivery systems, Lyon, France, 1991).

67\. Cottrell DA, **[Osei K]{.underline}**, Kirkpatrick RB, O\'Dorisio
TM, Malarkey WB, Henry ML, Tesi RJ. Glucose homeostasis following
hepatic denervation in humans: The role of counterregulatory hormones.
(Presented at the American Diabetes Association National Meeting, San
Antonio, TX, 1992). Diabetes 1992;41(suppl 1):247.

68\. **[Osei K]{.underline}**, Cottrell DA, Bossetti BA. Black-white
differences in insulin sensitivity and glucose effectiveness. (Presented
at the American Diabetes Association National Meeting, San Antonio, TX,
1992). Diabetes 1992;41(suppl 1):236.

\*69. Cottrell DA, **[Osei K]{.underline}**, Kirkpatrick RB, O\'Dorisio
TM, Malarkey WB, Henry MB, Tesi RJ. Significance of hepatic innervation
in glucose responses to insulin-induced hypoglycemia in humans.
(Presented at American Federal for Clinical Research National Meeting,
Baltimore, MD, May, 1992). Clin Res 1992;40:238A.

\*70. Cottrell DA, **[Osei K]{.underline}**, Henry ML, O\'Dorisio TM,
Tesi RJ. Longterm non-beta islet cell function after pancreas
transplantation in IDDM recipients (Presented at the American Federation
for Clinical Research National Meeting, Baltimore, MD, 1992). Clin Res
1992;40:281A.

\*\*71. **[Osei K]{.underline}**, Cottrell D, Bossetti B. Impact of
family history of NIDDM on insulin sensitivity in black Americans.
(American Federation for Clinical Research Regional Meeting, Chicago,
November, 1992). Clin Res 1992;40:689A.

\*\*72. Cottrell D, Gelfand R, Cataland S, O\'Dorisio T, Casey C,
**[Osei K]{.underline}**. Insulinotropic effect of GLP-1(7-37) in NIDDM
patients: A study of dose and glucose dependency. (American Federation
for Clinical Research Regional Meeting, Chicago, November, 1992). Clin
Res 1992;40:734A.

\*73. Cottrell D, Schuster D, O\'Dorosio T, **[Osei K.]{.underline}**
Suppressibility of insulin secretion during hypoglycemia in Type 1
diabetic pancreas allograft recipients. (American Federation of Clinical
Research National Meeting, Washington,DC, April, 1993). Clin Res
1993;41:237A.

\*74. **[Osei K]{.underline}**, Henry M, Tesi R, Ferguson R. Assessment
of insulin sensitivity and glucose-dependent glucose disposal in human
resistant models. (American Federation for Clinical Research National
Meeting, Washington, DC, April, 1993). Clin Res 1993;41:300A.

75\. **[Osei K]{.underline}**, Cottrell D, Adeuwon C, Ezenewaka C,
Akanji A, O\'Dorisio T. Impact of obesity and family history of NIDDM on
insulin and glucose in African-Americans and Nigerians. (American
Federation for Clinical Research National Meeting, Washington, DC,
April, 1993). Clin Res 1993;41:358A.

76\. **[Osei K]{.underline}**, Schuster D, Sparks E, Boudoulas H, Wooley
C. Black-White differences in insulin sensitivity, aortic distensibility
and pulse wave velocity. (American Federation for Clinical Research
National Meeting, Washington, DC, April, 1993). Clin Res 1993;41:359A.

\*77. **[Osei K]{.underline}**, Schuster D, Sparks E, Boudoulas H,
Vavuranakis M. Assessment of insulin sensitivity and cardiovascular
indices in healthy nondiabetic blacks and whites (American Diabetes
Association National Scientific Meeting, Las Vegas, June, 1993).
Diabetes 1993;42(suppl 1):28A.

\* 78. Cottrell D, Schuster D, **[Osei K]{.underline}**.
Counterregulatory responses to hypoglycemia in Type 1 diabetic pancreas
allograft recipients. (American Diabetes Association National Scientific
Meeting, Las Vegas, June, 1993). Diabetes 1993;42(suppl 1): 52A.

\*79. Cottrell D, **[Osei K]{.underline}**. Natural history of glucose
homeostasis and insulin sensitivity in type 1 diabetic pancreas
transplant recipients. Diabetes 1994;43: 434.

\*80 **[Osei K.]{.underline}** Schuster defects of migration on serum
glucose, beta cell function and insulin sensitivity in persons of
African blacks and recent African immigrants (Presented at Midwest
American Federation of Clinical Research; 42:168

\*81 Schuster P. **[Osei K.]{.underline}** The impact of insulin
sensitivity on blood pressure and heart rate in African Americans and
recent African immigrants( Midwest Regional Meeting, American Federation
of Clinical Research, 1994; 42: 169

\*82 **[Osei K.]{.underline}** Schuster DA. Ethnic differences in
sensitivity, secretion and hepatic

extraction of insulin in black and white Americans. Presented at the
15th,

International Diabetes Federation Congress, Kobe, Japan, Nov 6-11, 1994;

PP0652

\*83. **[Osei K]{.underline}**. Schuster DA, Ethnicity and glucose
regulation: Implications of

westernization in people of African descent. Clin Res. 43 Supp l3, 461

\*84. Schuster DA, **[Osei K,]{.underline}** Enhanced insulin
sensitivity and decreased Beta cell

function in obese Prader Willi Syndrome: A Minimal Model Analysis. Clin
Res 43, Suppl 3, 481, 1995

\*85. Gaillard T, **[Osei K]{.underline}**, Schuster DP, Bossetti B,
Greeen P. Sociodemographic characteristics do not predict NIDDM in high
risk African Americans((Submitted to American Diabetes Association
Scientific Meeting, San Francisco, June 1996)

Diabetes 1996, 45, Suppl 2, 531

\*86. Schuster D, **[Osei K,]{.underline}** Kien CL, Effects of race on
peripheral and hepatic glucose

metabolism in African American and Caucasian adolescents Presented at
the American Federal of Clinical Research, Washington DC, May 1996,
Clinical Research, 1996, 44,223A

\*87. **[Osei K,]{.underline}** Schuster DP, Gaillard T.
Characterization of determinants of glucose

intolerance and NIDDM in African Americans using minimal model analysis

> Presented to American Federal of Clinical Research, Washington, DC,May
> 1996) Clinical Research, 1996, 44, 222A

\*88. Schuster DP, **[Osei K]{.underline}**, Zipf WB, Characterization
of early glucose homeostasis,

> insulin secretion and hepatic insulin extraction in nondiabetic obese
> Prader - Willi patients and healthy control subjects( Submitted to
> American Pediatric Society for Pediatric Research, Clinical Research,
> Washington,DC, May 1996)

89. **[Osei K]{.underline}**, Gaillard T, Schuster D. History of
    gestational diabetes predicts severe

> metabolic defects in African Americans with parental history of type 2
> diabetes. (To be presented at Professional Scientific Session,
> American Diabetes Association Meeting, Boston, June 1997)

\*90. **[Osei K]{.underline}**, Gaillard T, Schuster D. Syndrome X: Does
it exist in high risk, first

degree relatives of African American patients with type 2 diabetes?(To
be presented at Professional Scientific Session, American Diabetes
Association Meeting, Boston, June 1997)

\*91. Gaillard T, Schuster D, **[Osei K.]{.underline}** Gender
differences in cardiovascular risk factors in African Americans at risk
for type 2 diabetes.(To be presented at Professional Scientific Session,
American Diabetes Association Meeting, Boston, June 1997)

\*92. Gaillard T, Schuster D, **[Osei K]{.underline}** The impact of
parental history on quality of life in

African Americans at high for type 2 diabetes.(To be presented at
Professional

Scientific Session, American Diabetes Association Meeting, Boston, June
1997)

93. Schuster D, Gaillard T, Boudoulas H, Sparks L, **[Osei
    K.]{.underline}** Early cardiovascular

differences in African Americans with varying degrees of impaired
glucose

tolerance.(Submitted American Diabetes Americans, 1997)

\*94. Schuster D, Gaillard T, Boudoulas H, Sparks L, **[Osei
K.]{.underline}** The relationship of

cardiovascular indices and insulin sensitivity in African Americans with
glucose

intolerance.(To be presented at Professional Scientific Session,
American Diabetes Association Meeting, Boston, June 1997)

\*95. **[Osei K]{.underline}**, Gaillard T, Schuster D. Clustering of
abnormal lipid and lipoprotein

concentrations is not associated with alterations in serum insulin
levels in African

Americans at high risk for type 2 diabetes American Federation of

Medical Sciences, Washington, DC, 1998

\*96. Schuster D, Gaillard T. [Osei K.]{.underline} Comparison of
Minimal Model and Homeostasis Model Assessment Parameters in African
Americans (American Diabetes Association, San Diego, June 1999) Diabetes
Suppl, 48, 0378, 1999

\*97. Schuster D. Gaillard T, Osei K. Changes in OGTT associated with
low dose metformin therapy in nondiabetic, at risk African Americans
(American Diabetes Association, San Diego, June 1999). Diabetes
Suppl..49, 379, 2000

\*98. Gaillard T, Schuster D [Osei K.]{.underline}The effects of low
dose Glipizide (GITS) in nondiabetic first degree relatives o patients
with type 2 diabetes, Diabetes Suppl. 49, 1361, 2000

\*99. Burgun SJ, Gaillard TR, Habash D, Osei K,. Macronutrient
enrichment shows no differential effect on Postprandial energy
expenditure in young women. Diabetes 49,Suppl 1 Abstract \# 163, 2000

**[\*]{.underline}100. [Osei K]{.underline}**, Gaillard T, Schuster D.
Restoration of altered glucose dysregulation by insulin sensitizers in
first degree relatives of African American patients with type 2 diabetes
Diabetes 20, Supple 2, 394,2001

\*101. Gaillard T, Schuster D, Boudoulas H, **[Osei K.]{.underline}**
Cardiovascular effects of insulin sensitizers in African Americans at
risk for type 2 diabetes. Diabetes 20, Supple 2, 373,2001

\*102 Schuster D, Gaillard T, Rogers J, **[Osei K.]{.underline}** Long
-term effects of oral antidiabetic medications on Insulin action and
beta cell function in African Americans with varying degrees of glucose
tolerance Diabetes 20, Supple 2, 149,2001

103\* **[Osei K,]{.underline}** Miller EE, Everitt DE, Ilgenfritz J,
Porter LE, Freed MI. Rosiglitazone is effective and well tolerated in
African Americans with type 2 diabetes. Diabetes 20, Suppl 2, 51,2001

\* Presented at National Scientific meetings

\*\* Presented at Regional Scientific meetings

**[PRESENTATIONS/LECTURES]{.underline}**

A. [National Meetings]{.underline} (see \* abstracts in previous
section)

**Invited Speaker**

1\. Epidemiology of diabetes. ADA Symposium for the National Medical
Association for Black Physicians, Orlando, FL, 1989.

2\. Symposium on Diabetes in African Americans: Contribution of insulin
resistance and beta cell dysfunction to glucose intolerance. Challenges
for the 90\'s symposium, Howard University College of Medicine and
Howard University Hospitals, Washington, DC, 1991.

3\. The insulin-taking type II diabetic: When and What? National Medical
Association, Indianapolis, IN August, 1991.

4\. Pathophysiology of type 2 diabetes, Guest Speaker, Scientific
Meeting of the National Medical Association of Black Physicians,
Indianapolis, IN, 1991.

5\. Rationale management of type 2 diabetes, Guest Speaker, Scientific
Meeting of The National Medical Association of Black Physicians, San
Francisco, CA, 1992.

6\. Application of minimal model analysis in pancreas transplantation.
The Third International Conference on Minimal Model, Baton Rouge, La
1994

7\. Ethnicity and insulin secretion and insulin action. World Congress
on Diabetes In the developing Countries, Accra, Ghana. May 1995

8\. Ethnicity and Insulin sensitivity: Symposium on Syndrome X, National
Institute of Health, Bethesda MD 1995

9\. Antidiabetic agents in the prevention of diabetes in high risk
African Americans, National Institute of Health, Bethesda, MD, 1995

10\. African American Diabetes Initiative, National American Diabetes
Association, Washington DC, 1996

11\. Diabetes and Obesity Conference, Seattle, .Washington,

12\. New Classification of diabetes: implications for drug prevention
treatment

13\. Pancreas Transplantation, Santiago, Chile

14\. New Strategies in the treatment of type 2 diabetes, Concepcion,
Conception Chile

15\. Insulin, insulin resistance and Cardiovascular diseases: Annual
Scientific Meeting of American College of Cardiology, Aneheim,CA, March,
1997

16\. Ethnicity and glucose regulation: Pathophysiologic implications
National Medical Association Scientific Meeting, Honolulu, Hawaii August
4th, 19997

17. Pathophysiology of type 2 diabetes: Implications for new therapies:
    Howard University Medical Center, Washington DC, 1998

18. Management of type 2 diabetes: New strategies. International Society
    of Hypertension(ISHIB), London, UK,1999

19. Overview of insulin resistance: Use of Monotherapy University of
    Washington, St Louis, Mo 1999

20. Ethnic differences in glucose regulation: National Meeting for
    Endocrine Society, San Diego, 1999

21. Management of type 2 diabetes: New strategies. International Society
    of Hypertension(ISHIB), Toronto, Canada 1999

22. Therapeutic Approaches o f Type 2 diabetes, Medical College of Ohio,
    Toledo, Ohio ,2000

23. Implications of UKPDS National ADA Symposium, Washington DC, 2000

24. Beta Cell Dysfunction in type 2 diabetes: Implications for
    treatment, National American Association of Clinical
    Endocrinologists(AACE) Atlanta, Ga, 2000

> 25\. Racial differences in diabetes; Georgetown University and Medstar
> Research Institute. Washington, DC, 2001
>
> [25]{.underline} Ethnicity and Diabetes: Is it the same disease?
> Tulane University, New Orleans, Louisiana, 2001

B. [Other academic institutions]{.underline}

**Visiting Professorship**

1\. Somatostatin agonist therapy: New Directions in Clinical Research,
University of Michigan, Ann Arbor, MI, 1990.

2\. Strategies in the management of difficult NIDDM patients, Rochester,
NY, 1993.

3\. New strategies in the management of type 2 diabetes: Is intensive
diabetic

> control achievable. University of Rochester Medical Center, Strong
> Memorial
>
> Hospital, Rochester, NY.1993

4\. Racial and ethnic basis for glucose and insulin metabolism.
Washington Hospital Center, George Washington University, Washington, DC
1994

5\. Evaluation of pancreas transplantation in IDDM. University of
California, Los Angeles 1994

6\. Genetic basis of type 2 diabetes; Lessons from MODY, New York
University Medical Center, New York 1995

7.  The importance of race and ethnicity type 2 diabetes in developing
    countries. Accra, Ghana, 1995

8.  Type 2 diabetes and Insulin resistance: Implications for new
    treatment modalities.

> Medical College of Ohio, Toledo, Ohio 2000

9.  New treatment strategies for type 2 diabetes: The role of beta cell
    dysfunction. American Association of Clinical Endocrinologists:
    Atlanta, Georgia, 2000

10. New treatment strategies for type 2 diabetes: The role of beta cell
    dysfunction. American Diabetes Association. San Antonio, Texas 2000

11. Targeting normal glycemic control: Prevention of Macrovascular
    complications, Dearborn, Illinois, 2001

12. Ethnicity and type 2 diabetes: Diabetes Symposium. March 2001,
    George Washington University. Washington DC. 2001

13. Ethnicity and glucose regulation: Implication sin the management of
    type 2 diabetes. Oklahoma University, Oklahoma City, 2001

C. [Ohio State]{.underline}

1\. Insulin resistance syndromes, part I. Ohio State University,
Columbus, OH, 1983.

2\. Insulin resistance syndromes, part II. Ohio State University,
Columbus, OH, 1983.

3\. Significance of ketonuria in phenotypically obese type II diabetic
patients. Ohio State University, Columbus, OH, 1983.

4\. Combination of insulin and sulfonylurea agent in the treatment of
type II diabetic patients: Does it work? Ohio State University, 1984.

5\. Acute complications of diabetes. Ohio State University, 1984.

6\. Endocrine causes of hypertension. Ohio State University Hospital,
Columbus, OH, 1985.

7\. Dietary management of diabetes. current trends. Grand Rounds, The
Ohio State University Hospital, Columbus, OH, 1985.

8\. Selection of drug therapy in type II diabetic mellitus: New
concepts. Grand Rounds, The Ohio State University Hospitals, Columbus,
OH, 1986.

9\. Diabetic ketoacidosis and hyperosmolar hyperglycemia, nonketotic
coma. The Ohio State University, Columbus, OH, 1986.

10. Selection of drug therapy in type II diabetes mellitus: New
    concepts. Grand Rounds,

11. The Ohio State University, Columbus, OH, 1986.

11\. Current strategies in treating type II diabetes. Grand Rounds:
Physical Rehabilitation Department, The Ohio State University, Columbus,
OH, 1986.

12\. Management of type II diabetes. Symposium on Diabetes, Ohio State
University School of Pharmacology, 1988

13. Insulin therapy: After 66 years. Medical Grand Rounds, The Ohio
    State University,

Columbus, OH, 1988.

14\. Potential role of insulin in cardiovascular disease. Division of
Cardiology, The Ohio State University, 1990.

15\. Racial differences in etiology of type 2 diabetes and hypertension.
Medical Ground Rounds, The Ohio State University Hospitals, Columbus,
OH, 1992.

16. New strategies in the treatment of type 2 diabetes; The Dawn of a
    New Era. Medical

Grand Rounds, The Ohio State University Hospitals, Columbus, Ohio, 1997

17. Management of type 1 diabetes: The role of islet cell
    transplantation and new technologies: Medical Ground Rounds. The
    Ohio State University, 2000

18. Targeting normal glycemic control: Prevention of Macrovascular
    complications, Toledo, Ohio, 2001

19. Diabetes and Cardiovascular Disease: Yesteryear. Today and Tomorrow:
    Medical College of Ohio, Toledo, 2001

**D. [Non-academic institutions]{.underline}**

1\. Current trends in diabetes. VA Clinic, Columbus, OH, 1983.

2\. Drug therapy in hypertension. VA Clinic, Columbus, OH, 1983.

3\. Management of diabetes mellitus: use of C‑peptide determination. VA
Clinic, Columbus, OH, 1983.

4\. Discussant: Cyclic Cushing\'s syndrome. Wright‑Patterson Air Force
Base, Dayton, OH, 1984.

5\. Discussant: Secondary hypopituitarism after pituitary surgery.
Kettering Hospital, Dayton, OH, 1984.

6\. Discussant: Hypogonadism. VA Medical Center, Chillicothe, OH, 1984.

7\. Discussant: Pituitary tumor. VA Medical Center, Chillicothe, OH,
1984.

8\. Discussant: Hypercalcemia. Kettering Hospital, Dayton, OH, 1984.

9\. Discussant: SIADH is a 69 year old female with metastatic carcinoma
of the breast. Kettering Hospital, Dayton, OH, 1984.

10\. Discussant: Myxoedema psychosis. St. Elizabeth Hospital, Dayton,
OH, 1984.

11\. Discussant: Selection of drug therapy in type II diabetics. Wright
Patterson AFB, Dayton, OH, 1984.

12\. Classification & management of diabetes mellitus. VA Clinic,
Columbus, OH, 1984.

13\. Concomitant insulin and sulfonylurea therapy in type II diabetic
patients. VA Clinic,Columbus, OH, 1984.

14\. Classification and management of lipoprotein dysfunctions. VA
Clinic, Columbus, OH, 1984.

15\. Peripheral vascular disease in diabetes mellitus. VA Clinic,
Columbus, OH, 1984.

16\. Endocrine causes of hypertension. VA Clinic, Columbus, OH, 1984.

17\. Acute complications of diabetes: Diabetic ketoacidosis vs.
hyperglycemic, hyperosmolar non‑ketotic coma. VA Clinic, Columbus, OH,
1984.

18\. Hyperthyroxinemia: Is it thyrotoxicosis? VA Clinic, Columbus, OH,
1984.

19\. The use of second generation sulfonylurea agents in type II
diabetes mellitus. VA Clinic, Columbus, OH 1984.

20\. Evaluation of hypertensive patients: endocrine causes. VA Hospital,
Chillicothe, OH, 1984.

21\. Management of diabetes: current trends. VA Hospital, Chillicothe,
OH, 1984.

22\. Discussant: (1) Euthyroid sick syndrome in an elderly patient with
congestive heart failure and hepatic congestion, (2) 20 yr old female
with galactorrhea and prolactin level of 40 ng/ml. Kettering Hospital,
Dayton, OH, 1985.

23\. Discussant:28 yr old with infectious mononucleosis and acute
Graves\' disease. St. Elizabeth Hospital, Dayton, OH, 1985.

24\. Discussant: Hyperthyroxinemia. VA Medical Center, Chillicothe, OH,
1985.

25\. Discussant: Hypercalcemic states. VA Medical Center, Chillicothe,
OH, 1985.

26\. Discussant: Drug selection in type II diabetic patients: VA Medical
Center, 1985.

27\. Clinical and laboratory assessment of hypothyroid patients. VA
Clinic, Columbus, OH, 1985.

28\. Atherogenesis in diabetes: new insights. VA Clinic, Columbus, OH,
1985.

29\. Dietary management of diabetes. VA Clinic, Columbus, OH, 1985.

30\. Clinical evaluation of diabetic patients. VA Clinic, Columbus, OH,
1985.

31\. Drug treatment of diabetic patients. VA Clinic, Columbus, OH, 1985.

32\. Chronic complications of diabetic patients I and II. VA Clinic,
Columbus, OH, 1985.

33\. Discussant: Selection of drug therapy in type II diabetic patients.
VA Medical Center, Chillicothe, OH, 1986.

34\. Discussant: Strict glucose control: effects on micro‑ and
macro‑angiopathic complications of diabetes. Mercy Medical Center,
Springfield, OH, 1986.

35\. Discussant: Evaluation of chronic diabetic complications. VA
Medical Center, Chillicothe, OH, 1986.

36\. Discussant: Hyperosmolar nonketotic coma. Kettering Hospital,
Dayton, 1986.

37\. Discussant: Drug selection in type II diabetic patients: clinical
indexes. Wright‑Patterson Air Force Base, 1986.

38\. Discussant: Diagnosis and management of diabetes. St. Elizabeth
Medical Center, 1986.

39\. Discussant: Heterogeneity of type II diabetes. VA Medical Center,
Chillicothe, 1986.

40\. Discussant: What is a diabetic diet? \"Real or Fallacy\". VA
Medical Center, Chillicothe, OH, 1986.

41\. Endocrine Review. VA Clinic, Columbus, OH, 1986.

42\. Pathophysiology of diabetes. VA Clinic Columbus, OH, 1986.

43\. Diet in the management of diabetes. VA Clinic, Columbus, OH, 1986.

44\. Chronic diabetic complications. VA Clinic, Columbus, OH, 1986.

45\. Discussant: Diabetes: What is new here and abroad? Does strict
control make a difference? Holzer Medical Center, Gallipolis, OH, 1987.

46\. Discussant: Diabetes: What is the hope for the future? Holzer
Medical Center, Gallipolis, OH, 1987.

47\. Discussant: Combination of insulin and oral sulfonylurea agents in
type II diabetes. Timken Hospital, Canton, OH, 1987.

48\. Discussant: Insulin resistance in diabetes: Effects of drug
treatment. Miami Valley Hospital, Dayton, OH, 1987.

49\. Discussant: Hypertension in diabetes. VA Medical Center,
Chillicothe, OH, 1987.

50\. Discussant Overview of management of type II diabetes mellitus: New
strategies. St Elizabeth Hospital, Dayton, OH, 1987.

51\. Discussant: Management of type II diabetes. VA Medical Center,
Chillicothe, OH, 1987.

52\. Hypoglycemia. Grant Hospital, Columbus, OH, 1987.

53\. Hypercalcemia. Grant Hospital, Columbus, OH, 1987.

54\. Insulin administration. VA Clinic, Columbus, OH, 1987.

55\. Hypercalcemia in an elderly patient: differential diagnosis. Mount
Carmel Medical Center, Columbus, OH, 1987.

56\. Discussant: Hypopituitarism and hyperlipidemia. VA Medical Center,
Chillicothe, OH, 1988.

57\. Discussant: Lipids: New drug therapy. St. Francis Hospital,
Charleston, WV, 1988.

58\. Discussant: Pituitary tumors and empty sellar syndrome. St.
Elizabeth Hospital, Dayton, OH, 1988.

59\. Case studies in Endocrinology I and II. VA Clinic, Columbus, OH,
1988.

60\. Discussant: Pharmacologic therapy for hyperlipidemia. Coshocton
Memorial Hospital, Coshocton, OH, 1989.

61\. Peripheral vascular disease and diabetes. VA Clinic, Columbus, OH,
1989.

62\. Hyperparathyroidism. VA Medical Center, Chillicothe, OH, 1989.

63\. Autoimmune polyglandular failure syndrome, VA Clinic, Columbus, OH,
1989.

64\. Discussant: Hypernatremia in diabetes mellitus. St. Elizabeth
Hospital, Dayton, OH, 1989.

65\. Discussant: Lipids in 1990. Wheeling Hospital, Wheeling, WV, 1989.

66\. Discussant: Insulin therapy in 1990. VA Medical Center,
Chillicothe, OH, 1990.

67\. Discussant: Hyperlipidemia and diabetes: Postgraduate Day in Family
Practice, Wheeling, WV, 1990.

68\. Insulin therapy in 1990. VA Medical Center, Columbus, OH 1990.

69\. Diabetes and Hypertension. VA Medical Center, Columbus, OH 1990.

70\. HDL- and Cardiovascular Disease: Physician Recognition Day, VA
Medical Center, Chillicothe, OH, 1990.

71\. Hypoglycemia: Central Ohio Diabetes Association Scientific Meeting,
Columbus, OH 1990.

72\. Cardiovascular Risk Factors: Importance of HDL-cholesterol, Greene
Medical Center, Xenia, OH, 1990.

73\. Lipoprotein Metabolism and Diabetes. Lancaster Hospital, Lancaster,
OH, 1990.

74\. Discussant: Management of type 2 diabetes. St. Elizabeth\'s
Hospital, Dayton, OH 1991.

75\. Discussant: The use of c-peptide in the management of type 2
diabetes, WPAFB, Dayton, OH, 1991.

76\. Discussant: Hyperlipidemia and diabetes. Riverside Methodist
Hospital, Columbus, OH, 1991.

77\. Discussant: Classification of diabetes: Global views. VA Medical
Center, Chillicothe, OH, 1991.

78\. Discussant: Hypocalcemia. St Elizabeth\'s Hospital, Dayton, OH,
1991.

79\. Interpretation of thyroid function tests. Mount Carmel West Grand
Rounds, Columbus, OH, 1991.

80\. Thyroid function abnormalities: The use of ultra sensitive TSH
assays. VAOPC, Columbus, OH, 1991.

81\. Hyperlipidemia in clinical practice: Who to treat. Progressive
Health Care, Columbus, OH, 1991.

82\. Discussant: Thyroid nodule in a 58 year-old male. St. Elizabeth\'s
Hospital, Dayton, 1992.

83\. Discussant: Management of primary hyperparathyroidism, Wright
Patterson Air Force Base, 1992.

84\. Non-insulin-dependent diabetes and hypertension in black and white
Americans: The insulin link. VA Clinic, Columbus, OH, 1992.

85\. Strategies in the management of type 2 diabetes: Local general
practitioners, Columbus, OH, 1992.

86\. Modern treatment of type 2 diabetes: Ground Southwestern General
Hospital, Cleveland, OH, 1994

**[Other]{.underline}s**

1\. Selection of drug therapy in type II diabetic patients using
clinical parameters. Central Ohio Diabetes Association Meeting,
Columbus, OH, 1985.

2\. Dietary carbohydrate in diabetes: new insights. American Diabetes
Association, local meeting, Columbus, OH, 1988.

3\. Discussant: New strategies in the treatment of NIDDM, Wooster
Medical Society, Wooster, OH, 1990.

4\. Pancreas transplantation. CODA Women\'s Board, Columbus, OH, 1991.

5\. Classification of diabetes: Controversies and pitfalls. Annual
American

Diabetes Association (ADA) Scientific section, Columbus, OH, 1991.

6\. The role of HDL and triglyceride measurements in the management of

dyslipidemia. CHD lecture series, Richfield, OH, 1991.

7\. Identification and role of receptors in lipoprotein metabolism and
atherogenesis. CHD Lecture series, Columbus, OH, 1991.

8\. Coronary heart disease in the diabetic patients. CHD lecture series,
Columbus, OH 1991.

9\. Discussant: Evolution of type 2 diabetes and hypertension in black
Americans. Invited speaker, Black History Month, Columbus, OH, 1992.

10\. Prevalence of the complications of diabetes: Racial differences.
American Diabetes Association Regional Scientific Meeting, Columbus, OH,
1993.

11\. Advances in pancreas transplantation. CODA Patient Advocate Group,
Columbus, OH, 1993.

12\. Current research in diabetes. CODA, Washington Court House, OH,
1993.

13\. Classification of Diabetes Workshop: Ohio State Women Health
Issues, Columbus, Ohio 1995

14\. New Oral agents for type 2 diabetes, Greater Cleveland Diabetes
Association, Cleveland, Ohio 1995

15 New strategies in the management of type 2 diabetes, Ohio Association
of Physician Assistants, Columbus, Ohio, 1995

16\. Current treatment of type 2 diabetes, Fremont, California, 1996

17\. Round Table Conference on Diabetes in African Americans and
Minorities, Oakland, CA,1996

18\. New strategies in the management of type 2 diabetes; VA Columbus,
Ohio, 1996

19\. Overview of type 2 diabetes: VA Chillicothe, Ohio, 1996

20. Ethnic Differences in glucose regulation: Implications in the
    management of type 2

> diabetes: Lecture to The National Medical Association of Black
> Physicians, Columbus, Ohio 1996

21. New strategies in the management of type 2 diabetes. Lecture to The
    National Medical Association of Black Physicians, Columbus, Ohio
    1997

22. Update: Diabetes in the new millennium: Community Physicians,
    Columbus, Ohio 1998

23. Insulin therapy in diabetes: Community Physicians, Columbus, Ohio,
    1999,

24. Overcoming insulin resistance: Community Physicians, Toleda, Ohio
    2000

25. New oral antidiabetic medications: use of combination therapy.
    Columbus, Physicians, 2001